IP Library › Granted Patent US 7,354,740
Granted Patent B2
US 7,354,740 · App. 11/072,673 · Granted Apr 8, 2008

Animal product free system and process for purifying a

Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,354,740
App. No.
11/072,673
Granted
Apr 8, 2008
Kind
B2
Abstract

Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.

Claims (24)

1. An animal protein free (“APF”) process for purifying a biologically active botulinum toxin, the process comprising the steps of:

(a) obtaining a sample of a botulinum toxin fermentation culture, wherein the botulinum toxin fermentation culture results from a substantially APF process,

(b) contacting a hydrophobic interaction chromatography column resin with the culture sample so as to permit capture of a botulinum toxin by the hydrophobic interaction chromatography column;

(c) washing impurities off the hydrophobic interaction chromatography column;

(d) eluting the botulinum toxin from the hydrophobic interaction column;

(e) loading an ion exchange column chromatography column resin with the eluent from the hydrophobic interaction chromatography column;

(f) washing impurities off the ion exchange chromatography column, and;

(g) eluting the botulinum toxin from the ion exchange column, thereby obtaining a purified biologically active botulinum toxin through a process for purifying a botulinum toxin which is a substantially APF purification process.

2. The APF process of claim 1 , further comprising, after the step of obtaining a sample of a botulinum toxin fermentation culture and before the step of contacting a hydrophobic interaction chromatography column resin with the culture sample, the step of conditioning the clarified culture for hydrophobic interaction chromatography.

3. The APF process of claim 1 , further comprising, after the step of eluting the botulinum toxin from the hydrophobic interaction column and before the step of loading an ion exchange column chromatography column resin with the eluent from the hydrophobic interaction chromatography column, the step of conditioning the eluent from hydrophobic interaction column for ion exchange chromatography.

4. The process of claim 1 , wherein the botulinum toxin is a botulinum toxin type A, B, C, D, F, F or G.

5. The process of claim 1 , wherein the botulinum toxin is a botulinum toxin type A.

6. An APF process for purifying a biologically active botulinum toxin, the process comprising the steps of:

(a) obtaining a sample of a botulinum toxin fermentation culture, wherein the botulinum toxin fermentation culture results from a substantially APF process,

(b) conditioning the clarified culture for hydrophobic interaction chromatography;

(c) contacting a hydrophobic interaction chromatography column resin with the culture sample so as to permit capture of a botulinum toxin by the hydrophobic interaction chromatography column;

(d) washing impurities off the hydrophobic interaction chromatography column;

(e) eluting the botulinum toxin from the hydrophobic interaction column;

(f) conditioning the eluent from hydrophobic interaction column for ion exchange chromatography;

(g) loading an ion exchange column chromatography column resin with the conditioned eluent from the hydrophobic interaction chromatography column;

(h) washing impurities off the ion exchange chromatography column, and

(i) eluting the botulinum toxin from the ion exchange column, thereby obtaining a purified biologically active botulinum toxin through a process for purifying a botulinum toxin which is a substantially APF purification process.

7. The process of claim 6 , wherein the botulinum toxin is a botulinum toxin type A, B, C, D, F, F or G.

8. The process of claim 6 , wherein the botulinum toxin is a botulinum toxin type A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2005
From: XIANG, HUI; LUO, MINGJIANG; WANG, PING; DONOVAN, STEPHEN
To: ALLERGAN, INC.
Reel/Frame 016352/0001 →
Continuity (3)
Continuation In Part 1107205000 · Mar 3, 2005
Continuation In Part 1067287600 · Sep 25, 2003
Related Publication 20050238669A1 · Oct 27, 2005